Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Investment analysts at Wedbush boosted their FY2020 earnings per share estimates for shares of Sarepta Therapeutics in a note issued to investors on Monday. Wedbush analyst H. Behanna now forecasts that the brokerage will earn $2.37 per share for the year, up from their previous forecast of $2.33. Wedbush has a “Outperform” rating and a $72.00 price objective on the stock.

Several other research analysts have also recently issued reports on the company. Robert W. Baird restated an “outperform” rating and issued a $102.00 price objective on shares of Sarepta Therapeutics in a research note on Monday. Needham & Company LLC reiterated a “buy” rating and set a $81.00 price target on shares of Sarepta Therapeutics in a research report on Saturday. Cowen and Company reiterated an “outperform” rating and set a $64.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, October 5th. Piper Jaffray Cos. set a $68.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 4th. Finally, Jefferies Group set a $58.00 price target on Sarepta Therapeutics and gave the company a “hold” rating in a research report on Sunday, October 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $58.44.

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) traded down 0.39% on Tuesday, reaching $53.61. The company’s stock had a trading volume of 6,015,867 shares. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The company’s market capitalization is $2.57 billion. The firm has a 50-day moving average of $42.69 and a 200 day moving average of $25.96.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period last year, the company posted ($0.87) earnings per share.

Large investors have recently bought and sold shares of the stock. Emerald Mutual Fund Advisers Trust purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $4,712,000. First Midwest Bank Trust Division increased its stake in Sarepta Therapeutics by 36.2% in the second quarter. First Midwest Bank Trust Division now owns 32,954 shares of the company’s stock valued at $628,000 after buying an additional 8,754 shares in the last quarter. American Century Companies Inc. purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $651,000. Eagle Asset Management Inc. purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $6,756,000. Finally, Amici Capital LLC purchased a new stake in Sarepta Therapeutics during the first quarter valued at about $488,000. Hedge funds and other institutional investors own 65.29% of the company’s stock.

In related news, SVP David T. Howton sold 9,304 shares of the business’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $465,200.00. Following the sale, the senior vice president now owns 11,168 shares in the company, valued at approximately $558,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Edward M. Md Kaye sold 40,179 shares of the business’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total value of $2,410,740.00. Following the completion of the sale, the chief executive officer now owns 117,162 shares in the company, valued at approximately $7,029,720. The disclosure for this sale can be found here. 10.90% of the stock is owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.